

DDL2018

Posters

	POSTER BOARD NO
<p>Development of a theoretical model to predict pMDI spray force, using alternative propellant systems</p> <p><u>Barzin Gavtash</u>¹, Andy Cooper², Sarah Dexter², Chris Blatchford² & Henk Versteeg¹</p> <p>¹Loughborough University, Epinal Way, Loughborough, LE11 2TL, United Kingdom ²3M United Kingdom PLC, Charnwood Campus, 10 Bakewell Road, Loughborough, LE11 5RB, United Kingdom</p>	01
<p><i>In vitro</i> testing of the new Space Chamber Slim with salbutamol sulfate, fluticasone propionate, and ipratropium bromide pressurized metered dose inhalers</p> <p><u>Michael Nairn</u>¹, Andrew Lorbeer¹, Kurt Nikander², Scott Courtney¹</p> <p>¹Medical Developments International Limited, 4 Caribbean Drive, Scoresby, 3179, Australia ²InDevCo AB, Handbollsvagen 1B, Nykoping, 61164, Sweden</p>	02
<p>Evaluation of Pressurised Metered Dose Inhaler (pMDI) Plume Spray Force When a Valved Holding Chamber (VHC) is Present: A Proof of Concept Investigation to Identify Propensity for Premature Inhalation Valve Opening</p> <p><u>Mark W Nagel</u>¹, Jolyon P. Mitchell² & Jason A Suggett¹</p> <p>¹ Trudell Medical International, 725 Third Street, London, Ontario, NV5 5G4, Canada ² Jolyon Mitchell Inhaler Consulting Services Inc., 1154 St. Anthony Road, London, N6H 2R1, Canada</p>	03
<p>Hpmc Capsules In Dpis. Evaluation Of The Puncturing Force Using Capsules Made With Different Manufacturing Methods And Compositions</p> <p>Deepak Patil¹, Jnanadeva Bhat¹, Sanjay Powale¹, Ajay Giripunje¹, Justin Kalafat², <u>Fernando Diez</u>³</p> <p>¹ACG SciTech Center, 7 Prabhat Nagar Patel Estate, Jogeshwari (West), Mumbai, 400102, India ²ACG North America, LLC, 262 Old New Brunswick Rd, Piscataway, NJ, USA ³ ACG Europe, 159 Princes Gardens, W3 0LS, London, United Kingdom</p>	04
<p>Comparison of Aerosol Characteristics and Nicotine Delivery by Conventional Pharmaceutical Inhalation Devices and Electronic Nicotine Delivery Systems (ENDS)</p> <p><u>Weiling Li</u>, Qiang Wang, and Raymond W Lau</p> <p>Altria Client Services LLC, 601 E Jackson Street, Richmond, VA, 23219, U.S.A</p>	05
<p>Number size distribution of particles dosed by MDI and DPI inhalers</p> <p><u>Lucie Ondráčková</u>¹, Jana Kozáková¹, Jakub Ondráček¹, Vladimír Ždímal¹, Ludmila Mašková¹ & Stavros Kassinos²</p> <p>¹ Department of Aerosol Chemistry and Physics, Institute of Chemical Process Fundamentals of the CAS, Rozvojová 135, Prague, 165 02, Czech Republic ² Department of Mechanical & Manufacturing Engineering, University of Cyprus, 1 Panepistimiou Avenue, 2109 Aglantzia, Nicosia, Cyprus</p>	06

<p>Biopharmaceutics of (R)-roscovitine by Inhalation</p> <p><u>Magda Swedrowska</u>¹, Zachary Enlo-Scott¹, Laurent Meijer² & Ben Forbes¹</p> <p>¹Institute of Pharmaceutical Science, King's College London, 150 Stamford Street, London SE1 9NH, UK ²ManRos Therapeutics, Centre de Perharidy, Roscoff, 29680, France</p>	07
<p>Interpretation of manual actuation profiles from nasal unit-dose spray devices</p> <p><u>Benedicte Grosjean</u>¹, Gerallt Williams¹, Fabien Adam¹, David Chopard¹, Pierre Schwartz¹, Janick Cabiddu¹</p> <p>¹Aptar Pharma, Route des Falaises, Le Vaudreuil, 27100, France</p>	08
<p>Albumin as an alternative dispersion enhancer for inhalable siRNA spray dried powders</p> <p><u>Michael Y.T. Chow</u>¹, Philip C.L. Kwok², Hak-Kim Chan² & <u>Jenny K.W. Lam</u>¹</p> <p>¹Department of Pharmacology & Pharmacy, LKS Faculty of Medicine, The University of Hong Kong, 21 Sassoon Road, Pokfulam, Hong Kong ²Sydney Pharmacy School, Faculty of Medicine and Health, Pharmacy and Bank Building A15, The University of Sydney, Camperdown, NSW 2006, Australia</p>	09
<p>Understanding the motion of rotating hard shell capsules in dry powder inhalers</p> <p><u>Benedict Benque</u>¹ & Johannes Khinast¹</p> <p>¹Institute of Process and Particle Engineering, Graz University of Technology, Inffeldgasse 13, Graz 8010, Austria</p>	10
<p>Impact of Budesonide Particle Shape on Uptake by Respiratory Cells and Macrophages</p> <p><u>Sarah Zellnitz</u>¹, Marie-Theres Müller^{1,2} & Eleonore Fröhlich^{1,2}</p> <p>¹Research Center Pharmaceutical Engineering GmbH, Inffeldgasse 13, Graz, 8010, Austria ²Center for Medical Research, Medical University of Graz, Stiftingtalstraße 24, Graz, 8010, Austria</p>	11
<p>In silico Prediction of Pharmacokinetic Parameters after Cisplatin Intravenous and Endotracheal Administration Using GastroPlus™ Software</p> <p><u>Selma Chraibi</u>¹, Jessica Spires², Karim Amighi¹ & Nathalie Wauthoz¹</p> <p>¹Laboratory of Pharmaceutics and Biopharmaceutics, Faculty of Pharmacy, Université libre de Bruxelles (ULB), Boulevard du Triomphe, B-1050 Brussels, Belgium, schraibi@ulb.ac.be ²Simulation Plus, Inc., 42505 10th Street West, Lancaster 93534, United States of America (USA)</p>	12
<p>Dissolution Of Crystalline And Amorphous Particles In The Aerosol Phase</p> <p><u>Natalie Armstrong Green</u>¹, Allen Haddrell¹, Jonathan Reid¹, David Lewis² & Tanya Church²</p> <p>¹School of Chemistry, University of Bristol, Bristol, BS81TS, United Kingdom ²Chiesi Limited, Bath Road Industrial Estate, Chippenham, Wilts, United Kingdom</p>	13
<p>Characterisation of Nanomaterial in Nebulised Formulations for Clinical Products: Impact of Particle Size on Dissolution and Predicted Deposition Pattern.</p> <p><u>Carolyn Stevenson</u>¹, Henrik Kristensson¹, Karin Carlsson¹, Pia Mattsson¹, John Salomonsson¹, Jan Olof Svensson¹ and Ulrika Tehler¹</p> <p>¹ Pharmaceutical Sciences, IMED Biotech Unit, AstraZeneca Gothenburg, Sweden</p>	14

<p>Directly Probing the Dynamic Behaviour of Particles Originating from DPI and MDI Starting Formulations</p> <p><u>Allen Haddrell</u>¹, David Lewis², Tanya Church², Jonathan Reid¹</p> <p>¹University of Bristol, Bristol, UK ²Chiesi Farmaceutici S.p.A., Chippenham, UK</p>	15
<p>Relationship Between The Secondary Structure Of The Peptide Base siRNA Carrier And Effective Gene Silencing Effect On Lung Epithelial Cells</p> <p><u>Yingshan Qiu</u> ,¹ Bui Tam², Winne Y.W. Chung¹, James Mason² & Jenny K.W. Lam¹</p> <p>¹ Department of Pharmacology & Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, 21 Sassoon Road, Pokfulam, Hong Kong ² Institute of Pharmaceutical Science, King's College London, Franklin-Wilkins Building, 150 Stamford Street, London, United Kingdom</p>	16
<p>Ranking <i>In Vitro</i> Dissolution Of Orally Inhaled Drug Substance Powders In A Time-Efficient Manner</p> <p><u>Frans Franek</u>,¹ Linn Nilsson¹, Helena Thörn¹, Rebecca Fransson², Ulrika Tehler²</p> <p>AstraZeneca R&D, Pepparedsleden 1, Mölndal, 43183, Sweden ¹Pharmaceutical Technology & Development Inhalation, Operations ²Pharmaceutical Sciences, IMED</p>	17
<p>Targeted PEG-Poly(glutamic acid) Polymers For The Delivery of Proteins Into The Lung Epithelium</p> <p><u>Huitong Lucy Li</u>,¹Alejandro Nieto-Orellana¹, Franco H. Falcone¹, Cynthia Bosquillon¹, Gemma Keegan², Nick Childerhouse², Giuseppe Mantovani¹ and Snow Stolnik¹</p> <p>¹School of Pharmacy, University of Nottingham, University Park, Nottingham, NG7 2RD, UK. ²Vectura Group plc, One Prospect West, Chippenham, SN14 6FH, UK</p>	18
<p>Development of an <i>In Vitro</i> Solubility Test as a Tool for Predicting Lung Retention of Poorly Water Soluble Compounds</p> <p><u>Stefani Mariarita</u>¹, Cesari Nicola¹, Corsaletti Roberto¹, Fioni Alessandro¹, Saccani Francesca¹, Volta Roberta¹, Brogin Giandomenico¹ & Puccini Paola¹</p> <p>¹Chiesi Farmaceutici S.p.A., Largo Belloli 11/A, Parma, 43122, Italy</p>	19
<p>Systematic Development of an Inhaler Device for the Use in Horses: The EquiHaler[®]</p> <p><u>Herbert Wachtel</u>¹, Marcus Rahmel¹ Guido Endert² & Benjamin Franzmann³</p> <p>¹Boehringer Ingelheim Pharma GmbH & Co KG, Binger Strasse 173, 55216 Ingelheim, Germany ²DESIGNquadrat GbR, Schmiedhofsweg 1, 50769 Köln, Germany ³Boehringer Ingelheim Vetmedica GmbH, Binger Strasse 173, 55216 Ingelheim, Germany</p>	20

<p>Safety and effectiveness of sodium-colistimethate-loaded nanostructured lipid carriers (SCM-NLC) against <i>P. aeruginosa</i>: in vitro and in vivo studies following pulmonary and intramuscular administration</p> <p><u>C. Vairo</u>^{1,2}, <u>J. Basas</u>³, <u>M. Pastor</u>¹, <u>G. Gainza</u>¹, <u>M. Moreno-Sastre</u>^{2,4}, <u>X. Gomis</u>³, <u>A. Fleischer</u>^{5,6}, <u>E. Palomino</u>^{5,6}, <u>D. Bachiller</u>^{5,6}, <u>F.B. Gutiérrez</u>⁷, <u>J.J. Aguirre</u>^{1,7}, <u>A. Esquisabel</u>^{2,4}, <u>M. Igartua</u>^{2,4}, <u>E. Gainza</u>¹, <u>R.M. Hernandez</u>^{2,4}, <u>J. Gavalda</u>³ & <u>J.L. Pedraz</u>^{2,4}</p> <p>¹BioPraxis Research AIE, R&D Department, Hermanos Lumière, 5, 01510 Miñano (Araba), Spain</p> <p>²NanoBioCel Group, Laboratory of Pharmaceutics, University of the Basque Country, School of Pharmacy, Paseo de la Universidad 7, 01006 Vitoria-Gasteiz, Spain</p> <p>³Antimicrobial Resistance Laboratory, Vall d'Hebron Research Institute (VHIR). Infectious Diseases Department, Hospital Universitari Vall d'Hebron, Passeig de la Vall d'Hebron, 119-129, 08035 Barcelona</p> <p>⁴Biomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN). Vitoria-Gasteiz, Spain</p> <p>⁵Fundación Investigaciones Sanitarias Islas Baleares (FISIB), Development and Regeneration Program, Ctra. Sóller km 12, 07110 Bunyola (Balearic Islands), Spain</p> <p>⁶Consejo Superior de Investigaciones Científicas (CSIC), Ctra. Sóller km 12, 07110 Bunyola (Balearic Islands), Spain</p> <p>⁷Department of Pathological Anatomy, Hospital Universitario de Álava (HUA). José Atxotegi, 01009 Vitoria-Gasteiz, Spain</p>	<p>21</p>
<p>Telehealth Ready: Performance of the Amiko Respiro Sense connected technology with Merxin DPIs</p> <p><u>Philippe Roqueda</u>¹, <u>Martijn Grinovero</u>², <u>Luca Ponti</u>², <u>Graham Purkins</u>¹ & <u>Oliver Croad</u>¹</p> <p>¹Merxin Ltd, King's Lynn Innovation Centre, Innovation Way, King's Lynn, PE30 5BY, UK</p> <p>²Amiko Digital Health Limited, Salisbury House 31 Finsbury Circus, London, EC2M 5QQ, UK</p>	<p>22</p>
<p>Characterisation of Zinc Oxide as an Alternative to Aluminium Hydroxide in Nasal Vaccination</p> <p><u>Marie Hellfritzsich</u> & <u>Regina Scherließ</u></p> <p>Department of Pharmaceutics and Biopharmaceutics, Kiel University, Grasweg 9a, 24118 Kiel, Germany</p>	<p>23</p>
<p>Cannabidiol in a DPI – maximising the spray drying yield of HPMC matrix particles</p> <p><u>Tobias Gutowski</u> & <u>Regina Scherließ</u></p> <p>Department of Pharmaceutics and Biopharmaceutics, Kiel University, Grasweg 9a, 24118, Kiel, Germany</p>	<p>24</p>
<p>Spray dried powders for nasal application - Influence of particle morphology and filling process on aerosol generation</p> <p><u>Angelika Jüptner</u>¹, <u>Ségoène Sarrailh</u>² & <u>Regina Scherließ</u>¹</p> <p>¹Department of Pharmaceutics and Biopharmaceutics, Kiel University, Grasweg 9a, 24118 Kiel, Germany</p> <p>²Aptar Pharma, Route des Falaises, 27100 Le Vaudreuil, France</p>	<p>25</p>
<p>Assessment of Aerosol Delivery during Simulated Invasive Ventilation, Non-invasive Ventilation and High Flow Nasal Therapy</p> <p><u>Gavin Bennett</u>¹, <u>Mary Joyce</u>¹, <u>Louise Sweeney</u>¹ & <u>Ronan MacLoughlin</u>¹</p> <p>¹Aerogen, IDA Business Park, Dangan, Galway, Ireland</p>	<p>26</p>

<p>Softpellets for high dose pulmonary delivery</p> <p><u>Christian Etschmann</u>, Regina Scherließ</p> <p>Department of Pharmaceutics and Biopharmaceutics, Kiel University Grasweg 9a, 24118 Kiel, Germany</p>	27
<p>The Technical Challenges of the Developing Existing Inhalation Drug Products into New Metered Dose Inhaler Designs</p> <p><u>Neha Patel</u>, ¹ Alex Slowey¹ & Lester Harrison²</p> <p>¹3M Drug Delivery Systems Division (DDSD), Charnwood Campus, 10 Bakewell Road, Loughborough, Leicestershire, LE11 5RB, UK. ²3M Drug Delivery Systems Division (DDSD), 3M Center, St. Paul, MN 55144-1000, USA</p>	28
<p>Assessment of the effect of cannula choice and gas flow rate on aerosol delivery during high flow nasal therapy</p> <p><u>Louise Sweeney</u>¹, Mary Joyce¹, Gavin Bennett¹ & Ronan MacLoughlin¹</p> <p>¹Aerogen, IDA Business Park, Dangan, Galway, Ireland</p>	29
<p>High dose spray-dried powders for treating tuberculosis</p> <p>Mohammad Abdul Motalib Momin, Shubhra Sinha, Ian G Tucker & <u>Shyamal C Das</u></p> <p>School of Pharmacy, University of Otago, 18 Frederick Street, P.O. Box 56, Dunedin 9054, New Zealand</p>	30
<p>Impact of real time feedback from inhalation devices on patient satisfaction and adherence</p> <p><u>Bernhard Müllinger</u>¹, Tobias Kolb¹ & Tobias Gessler²</p> <p>¹Vectura GmbH, Robert-Koch-Allee 29, Gauting, 82131, Germany ²University of Giessen and Marburg Lung Center, Klinikstraße 33, Gießen, 35392, Germany</p>	31
<p>Performance of a New Polymer-Based Vibrating Mesh Nebulizer: A Comparison to Metal-Based Mesh Nebulizer</p> <p><u>Chen-Hsiang Sang</u>, Shih-Cherng Lin, Huang-Fei Chen, Hsin-Hua Tseng & Hsiao-Hui Lo</p> <p>Department of R&D, Medical Division, MicroBase Technology Corp., No.756, Jiadong Rd., Bade Dist., Taoyuan City, 33464, Taiwan (R.O.C.)</p>	32
<p>Developing clinically relevant methodology for existing pMDI aerosol products when coupled to the Intelligent Control Inhaler</p> <p><u>Russell Down</u>¹, Hayden Beresford¹, Chris Blatchford¹, Andy Cooper¹ & Stewart Griffiths¹</p> <p>¹3M Drug Delivery Systems Ltd, Charnwood Campus, 10 Bakewell Road, Loughborough, Leicestershire LE11 5RB</p>	33
<p>Experimental and Theoretical Investigation of a New Approach to In-Use Impactor Quality Specifications</p> <p><u>Daryl L. Roberts</u>¹, Mårten Svensson², Karolina Sandell², Dennis Sandell³</p> <p>¹Applied Particle Principles LLC, 17347 Westham Estates Court, Hamilton, VA 20158, USA ²Emmace Consulting AB, Medicon Village, S-223 81, Lund, Sweden ³S5 Consulting, Ekvägen 8, S-275 62, Blentarp, Sweden</p>	34

<p>Analytical Technology to Improve the Efficiency of a Through-Life Analysis on DPI Products</p> <p><u>Stefano Campo</u>¹, Lorena Gasparini¹, Federica Polimeni¹, Tatiana Salvo¹</p> <p>¹CMC, Drug Product Development Department, Chiesi Farmaceutici, Largo Belloli 11/A - 43122 - Parma - Italy</p>	35
<p>A closer look on the dispersion behaviour of Parateck[®] M DPI – based interactive mixtures: improving the fine particle fraction by the addition of fines</p> <p><u>Nancy Rhein</u>¹, Gudrun Birk² & Regina Scherließ¹</p> <p>¹Department of Pharmaceutics and Biopharmaceutics, Kiel University, Grasweg 9a, 24118 Kiel, Germany ²Merck KGaA, Frankfurter Straße 250, 64293 Darmstadt, Germany</p>	36
<p>Impact of Relative Humidity and Powder Filling Level on the Electrostatic Charging Behaviour of Different Capsule Types</p> <p><u>Thomas Wutscher</u>^{1,2}, Sarah Zellnitz¹, Mirjam Kobler³, Francesca Buttini^{1,4}, Laura Andrade⁵, Veronica Daza⁵, Alberto Mercandelli⁶, Stefano Biserni⁶, Susana Ecenarro Probst⁷, Johannes Khinast^{1,2} & Amrit Paudel^{1,2}</p> <p>¹ Research Center Pharmaceutical Engineering GmbH, Inffeldgasse 13, 8010 Graz, Austria ² Institute of Process and Particle Engineering, Graz University of Technology, Inffeldgasse 13, 8010 Graz, Austria ³ MEGGLE Excipients and Technology, Megglestraße 6-12, 83512 Wasserburg, Germany ⁴ Food and Drug Department, University of Parma, Parco delle Scienze 27, 43121 Parma, Italy ⁵ Laboratorios Liconsá, S.A. C/ El tejido 2, 19200 Guadalajara, Spain ⁶ MG2, Via del Savena 18, 40065 Pianoro, Bologna, Italy ⁷ Qualicaps Avda. Monte Valdelatas 4, 28108 Alcobendas, Madrid, Spain</p>	37
<p>Establishing the Vitrocell[®] Powder Chamber as a particle size-selective platform for <i>in vitro</i> dry powder testing</p> <p><u>S. Steiner</u>¹, M. Hittinger², K. Knoth², H. Gross², S. Frentzel¹, A. Kuczaj¹, J. Hoeng¹, M. Peitsch¹, T. Krebs³</p> <p>¹ PMI R&D, Philip Morris Products S.A., Quai Jeanrenaud 5, CH-2000 Neuchâtel, Switzerland ² PharmBioTec GmbH, Science Park 1, 66123 Saarbrücken, Germany ³ Vitrocell[®] Systems GmbH, Fabrik Sonntag 3, 79183 Waldkirch, Germany</p>	38
<p>Physicochemical characterisation of inhalation grade lactose after the removal of intrinsic fines.</p> <p><u>Ioanna Danai Styliari</u>¹, Arian Mobli¹ & Darragh Murnane¹</p> <p>¹School of Life and Medical Sciences, University of Hertfordshire, College Lane, Hatfield, AL10 9AB, UK</p>	39
<p>Acoustic Spectral Analysis on Lactose for inhaled formulation using UA-AFM</p> <p><u>Cedric Thomas</u>¹, N. Pocholle¹, E. Bourillot¹, L. Kerriou², V. Gamerre², E. Lesniewska¹</p> <p>¹ICB UMR CNRS 6303, Univ. Bourgogne Franche-Comté, Dijon, France ²Armor Pharma, Armor Proteines SAS, Saint Brice-en-Cogles, France</p>	40
<p>Probing Subtle Variabilities in Seretide/Advair Batches by Evaluation of Drug-Lactose Aerosol Interaction</p> <p><u>Larissa Gomes dos Reis</u>¹, Michele Pozzoli¹, Paul M Young^{1,2}, Robert Johnson²</p> <p>¹Woolcock Institute of Medical Research, University of Sydney, 431 Glebe Point Road, Sydney, NSW 2037, Australia ²Oz-UK Ltd, Unit 15, Lansdowne Court, Bumpers Way Chippenham Wiltshire, SN14 6RZ, UK</p>	41

<p>Application of Void Forming Index (VFI): Detecting agglomeration of mannitol with different physical properties</p> <p><u>Sunao Maruyama</u>¹, <u>Shuichi Ando</u>¹ and <u>Etsuo Yonemochi</u>²</p> <p>¹Formulation Technology Research Laboratories, Daiichi Sankyo Co., Ltd., 1-2-58, Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan</p> <p>²Department of Physical Chemistry, School of Pharmacy and Pharmaceutical Sciences, Hoshi University, 2-4-41, Ebara, Shinagawa-ku, Tokyo 142-8501, Japan</p>	42
<p>Safety cabinet for droplet size measurement by laser diffraction</p> <p><u>Aur�lie Dom�n�</u>¹, <u>Maria Cabrera</u>¹, <u>Michael Pasteur</u>², <u>Marguerite Tulli</u>³ & <u>Laurent Vecellio</u>¹</p> <p>¹ CEPR, INSERM U1100, University of Tours, 10 boulevard Tonnell�, Tours, 37032, France</p> <p>²Pharmacie Centrale des Arm�es, TSA 30004, Fleury-les-Aubrais cedex, 45404, France</p> <p>³Strat�gie Sant�, 19 rue Georges Cl�menceau, Versailles, 78000, France</p>	43
<p>Insights into DPI sensitivity to humidity and its correlation to formulation physicochemical characteristics: a temporal study using two commercial budesonide products</p> <p><u>J T Pinto</u>¹, <u>S Radivojev</u>^{1,2}, <u>E Fr�hlich</u>^{1,2} & <u>A Paudel</u>^{1,3}</p> <p>¹Research Center Pharmaceutical Engineering GmbH, Inffeldgasse 13, Graz, 8010, Austria</p> <p>²Center for Medical Research, Medical University of Graz, Stiftingtalstra�e 24, Graz, 8010, Austria</p> <p>³Institute of Process and Particle Engineering, Graz University of Technology, Inffeldgasse 13, Graz, 8010, Austria</p>	44
<p>Insights into humidity-induced changes on the <i>in-vitro</i> pulmonary deposition and the predicted plasma levels of budesonide from commercial DPIs: a pharmacokinetic model assisted risk assessment approach</p> <p><u>S Radivojev</u>^{1,2}, <u>J T Pinto</u>¹, <u>E Fr�hlich</u>^{1,2} & <u>A Paudel</u>^{1,3}</p> <p>¹Research Center Pharmaceutical Engineering GmbH, Inffeldgasse 13, Graz, 8010, Austria</p> <p>²Center for Medical Research, Medical University of Graz, Stiftingtalstra�e 24, Graz, 8010, Austria</p> <p>³Institute of Process and Particle Engineering, Graz University of Technology, Inffeldgasse 13, Graz, 8010, Austria</p>	45
<p>A European Pharmaceutical Aerosol Group (EPAG)-Led Cross-Industry Assessment of Inlet Flow Rate Profiles of Compendial DPI Test Systems: Part 1 – Experimental Data</p> <p><u>Jolyon P Mitchell</u>¹, <u>Chris Blatchford</u>², <u>Roland Greguletz</u>³, <u>Daryl L. Roberts</u>⁴, & <u>Henk Versteeg</u>⁵</p> <p>¹ Jolyon Mitchell Inhaler Consulting Services Inc., 1154 St. Anthony Road, London, N6H 2R1, Canada</p> <p>² 3M United Kingdom plc, Loughborough, LE11 5RB, UK</p> <p>³ Sofotec GmbH, Benzstra�e 1-3, Bad Homburg, D-61352, Germany</p> <p>⁴ Applied Particle Principles LLC, 17347 Westham Estates Court, Hamilton, VA 20158, USA</p> <p>⁵ Mechanical and Manufacturing Engineering, Loughborough University, Loughborough, LE11 3TU, UK</p>	46
<p>A European Pharmaceutical Aerosol Group (EPAG)-Led Cross-Industry Assessment of Inlet Flow Rate Profiles of Compendial DPI Test Systems: Part 2 – First-Order Impactor Model</p> <p><u>Daryl L. Roberts</u>¹, <u>Henk Versteeg</u>², <u>Chris Blatchford</u>³, <u>Roland Greguletz</u>⁴, <u>Jolyon P. Mitchell</u>⁵</p> <p>¹ Applied Particle Principles LLC, 17347 Westham Estates Court, Hamilton, VA 20158, USA</p> <p>² Mechanical and Manufacturing Engineering, Loughborough University, Loughborough, LE11 3TU, UK</p> <p>³ 3M United Kingdom plc, Loughborough, LE11 5RB, UK</p> <p>⁴ Sofotec GmbH, Benzstra�e 1-3, Bad Homburg, D-61352, Germany</p> <p>⁵ Jolyon Mitchell Inhaler Consulting Services Inc., 1154 St. Anthony Road, London, N6H 2R1, Canada</p>	47
<p>Formulating amikacin for dry powder inhalation</p> <p><u>I. Sibum</u>, <u>F. Grasmeijer</u>, <u>P. Hagedoorn</u> & <u>H.W. Frijlink</u></p> <p>Department of Pharmaceutical Technology and Biopharmacy, Ant. Deusinglaan 1, Groningen, 9713 AV, the Netherlands</p>	48

<p>Effect of spray dried formulation on the aerosol performance of a novel dry powder inhaler</p> <p><u>Serena Bonasera</u>¹, Dale R. Farkas², P. Worth Longest^{1,2} Bryce Beverlin II³ & Michael Hindle¹</p> <p>¹Department of Pharmaceutics, Virginia Commonwealth University, Richmond, VA, USA</p> <p>²Department of Mechanical and Nuclear Engineering, Virginia Commonwealth University, Richmond, VA, USA</p> <p>³Quench Medical Inc., St Paul, MN, USA</p>	49
<p>Spray dried composite powders: capsule filling process optimization and aerodynamic performance characterization</p> <p><u>Maria Braga</u>¹, Raquel Barros¹, Bruno Ladeira¹, Mariana F. Silva^{1,2}, Joana Tavares¹ & Eunice Costa¹</p> <p>¹Hovione FarmaCiencia SA, Sete Casas, 2674 – 506 Loures, Portugal</p> <p>²Research Institute for Medicines (iMed.Ulisboa), Faculdade de Farmácia, Universidade de Lisboa, Portugal</p>	50
<p>Innovation in manufacturing as applied to dry powder inhaler formulation.</p> <p>David A. Wyatt¹, Jasdip S. Koner¹, Eman Z. Dahmash¹ & Afzal R. Mohammed^{1,2}</p> <p>¹ Aston Particle Technologies Ltd., Aston University, Birmingham, B4 7ET, United Kingdom</p> <p>² Aston Pharmacy School, Aston University, Birmingham, B4 7ET, United Kingdom</p>	51
<p>Formulation of Inhalable Voriconazole Dry Powders Using Spray Freeze-Drying Technique</p> <p><u>Qiuying Liao</u>¹, Long YIP^{1,2} & Jenny K.W. LAM¹</p> <p>¹Department of Pharmacology & Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, 21 Sassoon Road, Pokfulam, Hong Kong</p> <p>²Department of Pharmacy and Forensic Science, King's College London, 150 Stamford Street, London, SE1 9NH, United Kingdom</p>	52
<p>An <i>In Vitro</i> Study to Rationalise Combination Therapies for Cystic Fibrosis Treatment</p> <p><u>Zara Sheikh</u>¹, Hui Xin Ong¹, Michele Pozzoli¹, Paul Young¹, Daniela Traini¹</p> <p>¹Woolcock Institute of Medical Research and Faculty of Medicine and Health, University of Sydney, 431 Glebe Point Road, Glebe NSW 2037, Australia</p>	53
<p>The Effect of Using a Turbulence Grid on Fluidization of Pharmaceutical Lactose Powder</p> <p><u>K. Elserfy</u>¹, S. Cheng¹, H-K. Chan³, G. Hebbink², M. Mehta² & A. Kourmatzis⁴</p> <p>¹ School of Engineering, Macquarie University, NSW 2109</p> <p>² DFE Pharma, Klever Strasse 187, 47568 Goch, Germany</p> <p>³ Advanced Drug Delivery Group, School of Pharmacy, The University of Sydney, NSW 2006</p> <p>⁴ School of Aerospace, Mechanical and Mechatronic Engineering, The University of Sydney, NSW 2006</p>	54
<p>Treating Lymphangioliomyomatosis with Inhaled Rapamycin Solid Lipid Nanoparticles</p> <p><u>Emelie Land</u>¹, Lyn M. Moir¹, Daniela Traini, Paul M. Young¹ & Hui Xin Ong¹</p> <p>¹Respiratory Technology, Woolcock Institute of Medical Research and Faculty of Medicine and Health The University of Sydney NSW, 2037, Australia</p>	55

<p>The Impact of Device Handling Errors upon Inhaled Medication Delivery from Pressurized Metered Dose Inhalers (pMDIs) Used with and without a Valved Holding Chamber (VHC)</p> <p><u>Jason A Suggett</u>¹, Mark W. Nagel¹ & Jolyon Mitchell²</p> <p>¹Trudell Medical International, 725 Third Street, London, Ontario, NV5 5G4, Canada ²Jolyon Mitchell Inhaler Consulting Services Inc., 1154 St. Anthony Road, London, N6H 2R1, Canada</p>	<p>56</p>
<p>Glycemic Profile in Rats After Pulmonary Administration of a Pure Insulin Powder</p> <p><u>Francesca Buttini</u>¹, Veronica Chierici¹, Eride Quarta¹, Lisa Flammini¹, Adryana Rocha Clementino¹, Susana Ecenarro², Massimiliano Tognolini¹, Elisabetta Barocelli¹, Paolo Colombo¹ & Ruggero Bettini¹</p> <p>¹Food and Drug Department, University of Parma, Parco Area delle Scienze 27a, 43124, Parma, Italy ²Qualicaps Europe, S.A.U., Alcobendas, Madrid, Spain</p>	<p>57</p>
<p>Inhaler Resistance, Flowrate and Duration of Inhalation: The Effort to Use an Inhaler Adequately</p> <p><u>Mark Sanders</u> & Ashley Green</p> <p>Clement Clarke International Limited, Edinburgh Way, Harlow, CM20 2TT, UK</p>	<p>58</p>
<p>Triple Therapy Aerosol Delivery from an Integrated Inhaler Technique Training Device</p> <p><u>Mark Sanders</u>¹ & Cuong Tran²</p> <p>¹Clement Clarke International Limited, Edinburgh Way, Harlow, CM20 2TT, UK ²2c Pharma Services, Cardiff Medicentre, Heath Park, Cardiff, CF14 4UJ, UK</p>	<p>59</p>
<p>Manufacturing DPIs: an engineering perspective</p> <p><u>Pietro Piera</u> & <u>Mathieu Pfeiffer</u></p> <p>IMA S.p.A., Via Emilia 428-442, 40064 Ozzano dell'Emilia (BO), Italy</p>	<p>60</p>
<p>Comparison of Aerosol Delivery Methods for Spontaneously Breathing Tracheostomy Patients</p> <p><u>Mary Joyce</u>, Sorcha Murphy, Gavin Bennett, Louise Sweeney & Ronan MacLoughlin</p> <p>Aerogen, Galway Business Park, Dangan, Galway, H91 HE94, Ireland</p>	<p>61</p>
<p>A Metal-Organic Framework (MOF) dry powder technology for antibiotic deep lung delivery and imaging</p> <p><u>Gabriela Wyszogrodzka</u>¹, Przemysław Dorożyński², Piotr Kulinowski³ & Stefano Giovagnoli⁴</p> <p>¹Department of Pharmacobiology Jagiellonian University Medical College, Medyczna 9, 30-068 Kraków, Poland ²Pharmaceutical Research Institute, Rydygiera 8, 01-793 Warszawa, Poland ³Department of Magnetic Resonance Imaging, Institute of Nuclear Physics, Polish Academy of Sciences, Radzikowskiego 152, 31-342 Kraków, Poland ⁴Department of Pharmaceutical Sciences, via del Liceo 1, University of Perugia, Perugia, 06123, Italy</p>	<p>62</p>
<p>Comparison of human cell lines for risk assessment of aerosolised pesticides</p> <p><u>Zachary Enlo-Scott</u>¹, Magda Swedrowska¹, Alex Charlton³, Leona Merolla³, Ian Mudway² & Ben Forbes¹</p> <p>¹Drug Delivery Research Group, Institute of Pharmaceutical Science, King's College London, 150 Stamford Street, London, SE1 9NH, United Kingdom ²MRC-PHE Centre for Environment and Health, Analytical, Environmental and Forensic Sciences, King's College London, 150 Stamford Street, London, SE1 9NH, United Kingdom ³Syngenta, Jealott's Hill International Research Centre, Bracknell, Berkshire, RG42 6EY, United Kingdom</p>	<p>63</p>

<p>Cyclodextrin-stabilised ion-pair complexes enhance drug lung uptake via the polyamine transporter</p> <p>Zarif M. Sofian¹, Julie T. W. Wang¹, Yuan L¹, Paul Royall¹, Ben Forbes¹, David J. Barlow¹, Clive Page^{1,2}, Khuloud T. Al-Jamal¹, Stuart Jones¹ & <u>Faiza Benaouda¹</u></p> <p>¹School of Cancer and Pharmaceutical Science, King's College London, 150 Stamford Street, London, SE1 9NH ²Sackler Institute of Pulmonary Pharmacology, King's College London, 150 Stamford Street, London, SE 1 9NH</p>	64
<p>Developing alternative models for <i>in vitro</i> investigation of excipient influence on drug transport</p> <p><u>Precious Akhmemokhan¹</u>, Magda Swedrowska¹, Josie Williams¹, Richard Harvey², Ben Forbes¹</p> <p><i>¹Institute of Pharmaceutical Science, School of Cancer and Pharmaceutical Sciences, King's College London</i> <i>²Institut für Pharmazie, Martin-Luther-Universität Halle-Wittenberg, Halle (Saale), Germany</i></p>	65
<p>Nasal Dry Powder Delivery: Implementing a formulation independent Spray Drying Process</p> <p><u>Mariana F. Silva^{1,2}</u>, Diana A. Fernandes^{1,2}, Maria Braga¹, António Eloy¹, João Marques¹, M. Luísa Corvo² & Eunice Costa¹</p> <p>¹Hovione FarmaCiência SA, Lumiar, 1649-038, Portugal ²Research Institute for Medicines (iMed.Ulisboa), Faculdade de Farmácia, Universidade de Lisboa, 1649-003, Portugal</p>	66
<p>Therapeutic Intranasal Drug Delivery: needleless treatment for epistaxis</p> <p>Larissa Gomes¹, Daniela Traini¹, Paul Young¹, & <u>Maliheh Ghadirj^{1,2}</u></p> <p>¹ Respiratory Technology, Woolcock Institute of Medical Research and Discipline of Pharmacology, Faculties of Medicine and Health, Sydney, Australia ² Faculty of Engineering and Information Technology, University of Technology Sydney (UTS)</p>	67
<p>Deposition in three nasal cast models with a new concept of nasal administration (Retronose) vs nasal spray</p> <p><u>Laurent Vecellio^{1,2}</u>, Deborah Le Pennec¹, Guillaume Grevin² & Alain Regard²</p> <p>¹ CEPR, INSERM U1100, University of Tours, Tours, France ²Nemera, La Verpilliere, France</p>	68

The Pat Burnell New Investigator Competition Finalists:	
<p>Gene Delivery to Lung Epithelial Cells Using a Cell Penetrating Peptide</p> <p><u>Larissa Gomes dos Reis</u>¹, Maree Svolos¹, Lyn M Moir¹, Rima Jaber², David Fecher², Norbert Windhab², Paul M Young¹ & Daniela Traini¹</p> <p>¹ Respiratory Technology, Woolcock Institute of Medical Research and Discipline of Pharmacology, Faculty of Medicine and Health, The University of Sydney, NSW, 2037, Australia ² Evonik Nutrition and Care GmbH, Kirschenallee, 64293, Darmstadt, Germany</p>	69
<p>Assessing Central and Peripheral Pulmonary Deposition of Three Fluticasone Propionate (FP) Dry Powder Inhaler (DPI) Formulations with Different Aerodynamic Particle Size Distributions (APSD) in Healthy Subjects via Population Pharmacokinetics Modeling</p> <p>Stefanie K Drescher¹, Mong-Jen Chen¹, Abhinav Kurumaddali¹, Uta Schilling¹, Yuanyuan Jiao¹, Jie Shao¹, Brandon Seay², Sandra M Baumstein³, Mutasim N. Abu-Hasan², Renishkumar Delvadia⁴, Lawrence Winner⁵, Christine Tabulov¹, Bavna Saluja⁴, Jag Shur⁶, Robert Price⁶, Michael Hindle⁷, Xiangyin Wei⁷, Murewa Oguntimein⁴, Denise S. Conti⁴, Juergen Bulitta¹ & Guenther Hochhaus¹</p> <p>¹Department of Pharmaceutics, College of Pharmacy, University of Florida, Gainesville, Orlando, FL, USA ²Division of Pediatric Pulmonary and Sleep Medicine, Department of Pediatrics, College of Medicine, University of Florida, Gainesville, FL, USA ³Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Gainesville, FL, USA ⁴Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA ⁵Department of Statistics, College of Liberal Arts & Sciences, University of Florida, Gainesville, FL, USA ⁶University of Bath, Bath, Great Britain ⁷Department of Pharmaceutics, Virginia Commonwealth University, Richmond, VA, USA</p>	70
<p><i>In Vitro</i> Activity of Inhalable Microparticles Containing Anti-Tb Drugs and an Efflux Pump Inhibitor against Mycobacteria Infections</p> <p>Irene Rossi¹, Francesca Buttini¹, Filippo Affaticati¹, Fabio Sonvico¹, Marco Pieroni¹, Elliott K Miller², Nitesh K Kunda², Pavan Muttil² & Ruggero Bettini¹</p> <p>¹University of Parma, Food and Drug Department, Parco Area delle Scienze 27/A, Parma, PR, Italy ²University of New Mexico, College of Pharmacy, Department of Pharmaceutical Sciences, 2705 Frontier Avenue NE, Albuquerque, NM, USA</p>	71
<p>Dry Powder Inhalation of Glucagon-like Peptide-1 for Management of Type-2 Diabetes Mellitus</p> <p><u>Sanketkumar Pandya</u>^{1,2}, Durgesh Kumar^{1,2}, Swati Gupta¹, Kalyan Mitra¹, Anil N Gaiwad¹ & Amit Misra¹</p> <p>¹CSIR-Central Drug Research Institute, Sector 10, Jankipuram Extension, Lucknow, 226031, India ²Academy of Scientific and Innovative Research, New Delhi - 110025, India</p>	72